The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.

1 month ago

Journal

IL6R (Interleukin 6 receptor)

Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)

BI26 More than skin deep: a case of eosinophilic fasciitis in a patient with relapsing-remitting multiple sclerosis. (PubMed, Br J Dermatol)

Her disease remains well controlled on methotrexate 15 mg once weekly. While the development of eosinophilic fasciitis in this case was presumed to be idiopathic, to our knowledge, this is the first case of eosinophilic fasciitis developing in the setting of long-term ocrelizumab use.

1 month ago

Journal

CRP (C-reactive protein)

methotrexate • Ocrevus (ocrelizumab)

Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)

P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Sep 2025 --> Dec 2025

1 month ago

Trial completion date

Ocrevus (ocrelizumab)

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. (PubMed, Int J Mol Sci)

This result implies that PBMCs' TNF mRNA expression might be potentially considered as a prognostic biomarker of ocrelizumab effectiveness in MS patients. However, further studies comprising large cohorts and additional immunological parameters are warranted.

1 month ago

Journal • Gene Expression Profile

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)

Ocrevus (ocrelizumab)

2ms

BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab. (PubMed, J Neuroinflammation)

This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.

2 months ago

Journal

SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • CDCP1 (CUB Domain Containing Protein 1) • GFAP (Glial Fibrillary Acidic Protein) • NEFL (Neurofilament Light Chain)

Ocrevus (ocrelizumab)

2ms

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy (clinicaltrials.gov)

P=N/A, N=111, Not yet recruiting, Region Stockholm | Initiation date: Oct 2025 --> Feb 2026

2 months ago

Trial initiation date

Rituxan (rituximab) • Ocrevus (ocrelizumab)

2ms

Ocrelizumab Access by Socio-Economic Status (clinicaltrials.gov)

P=N/A, N=800, Completed, Brigham and Women's Hospital | Not yet recruiting --> Completed | N=600 --> 800

2 months ago

Trial completion • Enrollment change • Real-world evidence

Ocrevus (ocrelizumab)

2ms

SurfSubQ: A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov)

P=N/A, N=842, Recruiting, Hoffmann-La Roche | N=349 --> 842 | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Nov 2026 --> Mar 2028

2 months ago

Enrollment change • Trial completion date • Trial primary completion date

Ocrevus (ocrelizumab)

2ms

PORTAMENTO: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov)

P2, N=182, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

Ocrevus (ocrelizumab)